Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-Scz-1: Brenipatide as Adjunctive Treatment in Schizophrenia
NCT07410507Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Primary completion
- Nov 2027
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Brenipatide + SoC with Placebo + SoC (2 arms). Primary endpoint: Percent Change from Baseline in Body Weight at 52 weeks. Started Feb 2026; status: recruiting.
02
Drugs
brenipatide
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07410507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410507.